Investor Moves
| Name | Value | Action | Change | Price | Last Price |
|---|---|---|---|---|---|
Ken GriffinCitadel Advisors $-14.7K TrimQ4 2025 $15k -- $1.70 | |||||
News
newsfilecorp.comOS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcomanewsfilecorp.comJun 2
newsfilecorp.comOS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery Worldnewsfilecorp.comMay 29
newsfilecorp.comOS Therapies Reports First Quarter 2026 Financials and Provides Business Updatenewsfilecorp.comMay 18
newsfilecorp.comOS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisornewsfilecorp.comMay 14
globenewswire.comBNP Paribas Primary New Issues:POST STAB Notice - NO STAB - CLARIANE TAPglobenewswire.comApr 30